GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,300 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
Ms. Katherine Stueland es el Chief Executive Officer de GeneDx Holdings Corp, se unió a la empresa desde 2022.
¿Qué tal es el rendimiento del precio de la acción WGS?
El precio actual de WGS es de $34.95, ha aumentado un 0.69% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de GeneDx Holdings Corp?
GeneDx Holdings Corp pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de GeneDx Holdings Corp?
La capitalización bursátil actual de GeneDx Holdings Corp es $1.0B
¿Es GeneDx Holdings Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 10 analistas han realizado calificaciones de análisis para GeneDx Holdings Corp, incluyendo 4 fuerte compra, 7 compra, 2 mantener, 0 venta, y 4 fuerte venta